|Articles|April 26, 2016
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
April 26, 2016.
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff
2
President Trump Planning to Fire FDA Commissioner Marty Makary: Report
3
Marty Makary Out as FDA Commissioner: Report
4
From Consulting to Venture Capital: A Q&A with Gibb Witham, President of Hack The Box
5